Apellis Pharmaceuticals, Inc.APLSNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank41
3Y CAGR-25.8%
5Y CAGR-30.8%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-25.8%/yr
vs -42.4%/yr prior
5Y CAGR
-30.8%/yr
Recent acceleration
Acceleration
+16.6pp
Accelerating
Percentile
P41
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 3.10% |
| Q3 2025 | 9.17% |
| Q2 2025 | 1.04% |
| Q1 2025 | 6.47% |
| Q4 2024 | -0.41% |
| Q3 2024 | -4.43% |
| Q2 2024 | -1.11% |
| Q1 2024 | -8.92% |
| Q4 2023 | -2.71% |
| Q3 2023 | 30.77% |
| Q2 2023 | 9.09% |
| Q1 2023 | 21.01% |
| Q4 2022 | 7.60% |
| Q3 2022 | 24.05% |
| Q2 2022 | 23.47% |
| Q1 2022 | 24.59% |
| Q4 2021 | -10.22% |
| Q3 2021 | -6.54% |
| Q2 2021 | 21.85% |
| Q1 2021 | -9.11% |
| Q4 2020 | 19.52% |
| Q3 2020 | 30.75% |
| Q2 2020 | -3.64% |
| Q1 2020 | 7.74% |
| Q4 2019 | 46.29% |
| Q3 2019 | 45.79% |
| Q2 2019 | 56.38% |
| Q1 2019 | 27.85% |
| Q4 2018 | 2.01% |
| Q3 2018 | 5.33% |
| Q2 2018 | 47.41% |
| Q1 2018 | -16.98% |
| Q4 2017 | 134.67% |
| Q3 2017 | 21.11% |
| Q2 2017 | -6.10% |
| Q1 2017 | 67.53% |
| Q4 2016 | 8.70% |
| Q3 2016 | -9.75% |
| Q2 2016 | 0.00% |
| Q1 2016 | -63.59% |